Watch PCVX. Know when insiders buy.
One email the day a filing lands. Free.
Work order
42
WATCH · insiders 40, shorts 44
Insiders, 90 days
−$212K
net selling · 0 buys, 4 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $9.1BP/E —DIV YIELD —FCF YIELD -9.82%REV TTM —NET INCOME −$1.1BNET CASH —52W 30.89 – 63.30SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$302.8M | −$284.3M | — | -1.97 | −$232.5M | $4.3M | −$236.8M | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$345.9M | −$320.6M | — | -2.30 | −$280.6M | $2.1M | −$282.7M | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$274.3M | −$246.5M | — | -1.80 | −$224.8M | $2.7M | −$227.5M | Feb 24 |
| Q3 2025 · Sep 30 | — | — | — | −$242.4M | −$212.8M | — | -1.56 | −$143.3M | $3.8M | −$147.1M | Nov 4 |
| Q2 2025 · Jun 30 | — | — | — | −$226.2M | −$166.6M | — | -1.22 | −$121.2M | $1.8M | −$123M | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | −$180.8M | −$140.7M | — | -1.04 | −$166.3M | $5.4M | −$171.7M | Aug 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$162.2M | −$137.1M | — | -1.02 | −$111.4M | $4M | −$115.4M | Feb 24 |
| Q3 2024 · Sep 30 | — | — | — | −$139.9M | −$103.1M | — | -0.83 | −$60.7M | $4.9M | −$65.7M | Nov 4 |
| Q2 2024 · Jun 30 | — | — | — | −$153M | −$128.7M | — | -1.10 | −$121.4M | $7.8M | −$129.2M | Nov 4 |
| Q1 2024 · Mar 31 | — | — | — | −$114.5M | −$95M | — | -0.85 | −$159.1M | $5.7M | −$164.8M | Nov 4 |
| Q4 2023 · Dec 31derived | — | — | — | −$196.7M | −$180.8M | — | -1.82 | −$128.8M | $5.3M | −$134.1M | Feb 24 |
| Q3 2023 · Sep 30 | — | — | — | −$113M | −$92.7M | — | -0.91 | −$57.5M | $7.3M | −$64.9M | Nov 5 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$923.7M | −$766.6M | — | -5.63 | −$655.6M | $13.7M | −$669.3M | — | — |
| FY2024 · to Dec 31 | — | — | −$569.5M | −$463.9M | — | -3.80 | −$452.6M | $22.4M | −$475.1M | — | — |
| FY2023 · to Dec 31 | — | — | −$468M | −$402.3M | — | -4.14 | −$296.8M | $16.1M | −$312.9M | — | — |
| FY2022 · to Dec 31 | — | — | −$232.3M | −$223.5M | — | -3.44 | −$170.6M | $5.8M | −$176.4M | — | — |
| FY2021 · to Dec 31 | — | — | −$103.7M | −$100.1M | — | -1.93 | −$121.4M | $6.6M | −$127.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$89.6M | −$89.2M | — | -3.02 | −$46.6M | $1.2M | −$47.8M | — | — |
Every number comes from Vaxcyte, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.